Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04594239. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
* Confirm the effectiveness of Belotero Balance® (+) Lidocaine (BBL) injection for the correction of volume loss in the infraorbital hollow (IOH) area by demonstrating superiority to untreated control. * Confirm the safety of BBL injection for the correction of volume loss in the IOH area.
Study identification
- NCT ID
- NCT04594239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Belotero Balance (+) Lidocaine, needle Device
- Belotero Balance (+) Lidocaine, cannula Device
- Untreated-control / delayed-treatment, needle Device
- Untreated-control / delayed-treatment, cannulas Device
Device
Eligibility (public fields only)
- Age range
- 22 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2020 (Actual)
- Primary completion
- Apr 8, 2021 (Actual)
- Completion
- Jun 21, 2022 (Actual)
- Last update posted
- Jan 30, 2024
2020 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Art of Skin MD, Merz Investigational Site #0010444 | Solana Beach | California | 92075 | — |
| Moradi MD Face Beautiful Inc., Merz Investigational Site #0010358 | Vista | California | 92083 | — |
| MetroDerm / Atlanta Center for Clinical Research, Merz Investigational Site #0010446 | Atlanta | Georgia | 30342 | — |
| Project Glammers, Merz Investigational Site #0010443 | Brooklyn | New York | 11229 | — |
| The Center for Dermatology, Cosmetic & Laser Surgery, Merz Investigational Site #0010442 | Mount Kisco | New York | 10549 | — |
| Mariwalla Dermatology, Merz Investigational Site #0010445 | West Islip | New York | 11795 | — |
| HKB Surgeons, Merz Investigational Site #0010447 | Huntersville | North Carolina | 28078 | — |
| Nashville Centre for Laser & Facial Surgery, Merz Investigational Site #0010353 | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04594239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2024 · Synced Nov 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.